• Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (²¹¹At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).
• Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.
• First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.
• Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for ²¹¹At develops.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome,  announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (²¹¹At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.

Astatine-211 is recognized as a promising alpha-emitting radioisotope for the development of innovative cancer treatments^[1]. However, its broader adoption remains constrained by the availability of sufficient production capacity^[2]. The collaboration is intended to improve robust, reliable, and timely access to ²¹¹At for research and clinical development through a network of production sites in close proximity to clinical centers, helping to further establish theranostics as a cornerstone of precision oncology.

For Telix, the collaboration is expected to support the development of several early-stage therapeutic candidates, including TLX102-Tx (²¹¹At astato-L-phenylalanine), a TAT being evaluated for glioblastoma and leptomeningeal disease, as well as future ²¹¹At programs. The collaboration is also intended to provide production capacity for third-party academic and industry programs, helping to expand the U.S. ²¹¹At development ecosystem.

Bruno Scutnaire, CEO of Ekalia (company in formation) said: "IBA's specialized alpha-beam cyclotron technology is designed to enable reliable astatine-211 production at the point of need. Building on our work with Framatome in Europe, Telix's U.S. infrastructure enables us to move faster towards establishing our first U.S. production unit, while laying the foundations for Ekalia's broader development in the country."

Chad Watkins, General Manager, Isotope Strategy at Telix, continued: "Owning the path from isotope to patient is central to our development and commercialization strategy. This collaboration gives Telix a dedicated, long-term source of astatine-211 to advance our alpha therapy pipeline, and demonstrates the strategic value of the RLS platform as a host for next-generation isotope production in the U.S. We are delighted to partner with IBA and Framatome, two global leaders in this field, to help advance reliable, scalable astatine-211 production."